Close menu

February 5th, 2024 | 07:45 CET

Is Bayer's share price about to jump? BYD off to a positive start! Manuka Resources with a billion-dollar opportunity!

  • Mining
  • Vanadium
  • Electromobility
  • chemicals
Photo credits: BYD Company Limited

Are Bayer shares on the verge of a price surge? According to analysts at Bernstein, the chemical company is significantly undervalued. Where does the optimism come from? Could there be a change in the Aspirin logo for Bayer in the near future? Chart-wise, the share is heavily battered. The chart for BYD also speaks a clear language. The electric vehicle manufacturer has reported a good start to 2024, while Manuka Resources' VTM iron sand project in New Zealand is generating share price fantasy. There is movement in the project, and following the capital increase, there is now an entry opportunity. Is the revaluation coming soon? The potential is in the billions.

time to read: 3 minutes | Author: Fabian Lorenz
ISIN: Manuka Resources Limited | AU0000090292 , BYD CO. LTD H YC 1 | CNE100000296 , BAYER AG NA O.N. | DE000BAY0017

Table of contents:

    Manuka Resources: After the capital increase, is a revaluation imminent?

    Is Manuka Resources facing a gigantic revaluation this year? It is certainly realistic. The Company is sitting on a billion-dollar project, namely the VTM Taranaki iron sands project. It is located 22 km to 36 km off the coast of New Zealand. The sand there contains vanadium, titanium and magnetite. The mining license has been granted and the environmental process is nearing completion. Following New Zealand's government change, the chances of exploration are increasing. In a recent interview with Kapitalerhö, Manuka Chairman Dennis Karp was extremely optimistic. Karp also emphasized the national importance of the project for New Zealand. In addition to millions in tax revenue, around 2,000 jobs would also be created. After mining, everything could be cleaned up in an environmentally friendly way within two years. Then Karp gets specific: The project has a fair value (NPV10) of USD 1.8 billion. In the past, there had already been a purchase offer at the equivalent of AUD 0.80 per share. The Manuka share is currently trading at AUD 0.08. Click here for the full interview.

    Manuka is already earning money with the Mt Boppy gold mine. The mine was ramped up in the second half of 2023 and is producing positive cash flows. To further expand Mt Boppy and to have funds for the development of Taranaki, Manuka successfully completed a capital increase of AUD 5 million last week. Of this, Manuka will receive AUD 2.5 million in cash directly. The other half was used to repay debt. As a result of the measure, the share price briefly fell to the issue price of AUD 0.07 but has already recovered to AUD 0.08 on Friday. Investors seem to have used the setback to enter the market.

    Bayer: Will Aspirin be sacrificed?

    Unfortunately, taking advantage of a price setback to enter the market has not paid off for Bayer in recent years. The DAX-listed company's share price has now fallen below the EUR 30 mark and has not seen this level for over 20 years – a real tragedy. The never-ending legal disputes and billion-euro payments relating to glyphosate are responsible for the decline. Even announced job cuts have not brought about a turnaround in the share price. The next hope for shareholders is the upcoming Capital Markets Day at the beginning of March. Bernstein analysts expect the announcement of drastic measures there. However, the separation from the agricultural sector is not anticipated. Instead, the analysts expect the sale of the over-the-counter medicines division, which includes the iconic Aspirin. Bayer without Aspirin may be unimaginable for many, but for the analysts at Bernstein, this could be a stroke of liberation. They rate Bayer shares as "Outperform". The price target is EUR 51 and thus significantly higher than the current EUR 28.69.

    However, the Bernstein analysts are quite alone in their optimism. Most analysts rate Bayer shares as "Neutral" or "Hold". UBS is no exception. Their price target is EUR 34. After the recent loss in the first instance trial, the risk of higher provisions is increasing. In addition, no exciting new drugs are on the horizon in the pharmaceutical sector, and existing drugs are under increasing pressure from generic products.

    BYD: Good start to the year leaves investors indifferent

    BYD is currently putting pressure on Tesla and other car manufacturers. The Chinese company has reported strong sales figures for January. In the first month of 2024, BYD sold 201,493 vehicles, representing an increase of around 33% compared to the 151,431 vehicles in January 2023. Notably, 36,174 vehicles were sold abroad. It will be interesting to observe how sales outside China develop this year. The share of pure electric vehicles (BEV) was around 48% (105,304 vehicles). **The comparison with December 2023 is less favourable. In the last month of the previous year, BYD sold 190,754 electric vehicles. The share may not have benefited from the sales figures on Friday. Analysts seem more concerned about the margin than the sales volume. Due to industry price wars, BYD's margin also fell significantly in the course of 2023.

    The BYD share will likely be driven less by sales figures than by earnings performance this year. Can the decline in margins be halted? Investors will have to keep an eye on this. At Manuka, ongoing gold production provides income, and the VTM iron sand project brings the share price fantasy. If exploration can indeed commence, a revaluation of the share is likely on the cards. There is little hope of a revaluation at Bayer. Legal disputes show no signs of ending, and the pharmaceutical pipeline is empty. A genuine upward trend would be a real surprise.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author

    Related comments:

    Commented by Juliane Zielonka on February 22nd, 2024 | 07:00 CET

    Royal Helium, Fresenius, BASF: Chemical and Healthcare industry - Where is the next investment opportunity?

    • Helium
    • Healthcare
    • chemicals

    Europe is in the midst of an industrial upheaval due to the Green Deal, which presents both challenges and opportunities for investors. While companies like BASF are arguing for deregulation and increased subsidies to support the green transition, healthcare company Fresenius is undergoing a period of radical change and realignment. The medical technology market is booming. The global MedTech market size amounted to USD 574,002.45 million in 2022 and is expected to increase to USD 814,159.2 million by 2028, with an annual growth rate of 6.0%. Critical raw materials such as helium are in particularly high demand. Royal Helium is one of the producers of this valuable gas and impresses with a well thought-out and sustainable business model. Where does the next investment opportunity lie?


    Commented by Armin Schulz on February 21st, 2024 | 07:30 CET

    Barrick Gold, Desert Gold, Renk - Golden times everywhere?

    • Mining
    • Gold
    • Defense

    The world is full of economic uncertainty and geopolitical tensions. These are ideal conditions for gold, which is still considered a safe haven. There are now several factors that point to a sustained upswing in gold prices. One factor is the increased involvement of central banks, which are increasing their reserves to an extent not seen for decades. Another factor is the discussion within the BRICS nations about introducing a new currency backed by gold as a counterweight to the dominant US dollar. Therefore, today, we look at two gold companies and shed light on Renk, a representative of the defense industry, which is also experiencing golden times.


    Commented by Juliane Zielonka on February 21st, 2024 | 07:15 CET

    Saturn Oil + Gas, Plug Power, Deutsche Pfandbriefbank - Energy shares and falling knives - where is it worth getting in?

    • Mining
    • Oil
    • Hydrogen
    • greenhydrogen
    • Banking

    The Canadian company Saturn Oil & Gas has announced its capital and operating budget plans for 2024. The main focus is on sustainable oil and gas production with high capital returns, a structured capital allocation and continuous rapid debt repayment. Plug Power is also gaining momentum and taking strong cost-saving measures to maintain its position at the forefront as a green hydrogen provider. Deutsche Pfandbriefbank (pbb) came under the spotlight last week as investors dumped shares due to its involvement in the US office real estate market. Is this bank a falling knife, or does this week offer a potential entry point? We provide the background.